{"id":61728,"date":"2024-03-06T08:40:14","date_gmt":"2024-03-06T08:40:14","guid":{"rendered":"https:\/\/medsname.com\/tavin-em\/"},"modified":"2026-05-10T08:48:12","modified_gmt":"2026-05-10T08:48:12","slug":"tavin-em","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/tavin-em\/","title":{"rendered":"Tavin EM"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Tavin EM?<\/h3>\n<p style=\"margin:0;\"><strong>Tavin EM<\/strong> obsahuje <strong>tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg<\/strong> a pou\u017e\u00edv\u00e1 se k profylaxi p\u0159ed expozic\u00ed HIV (PrEP) \u2014 prevenci infekce HIV-1 u HIV-negativn\u00edch dosp\u011bl\u00fdch se zna\u010dn\u00fdm rizikem. P\u0159i denn\u00edm u\u017e\u00edv\u00e1n\u00ed s vysokou adherenc\u00ed sni\u017euje PrEP zalo\u017een\u00fd na TDF\/FTC riziko infekce HIV o <strong>&gt;99 % p\u0159i denn\u00edm u\u017e\u00edv\u00e1n\u00ed s vysokou adherenc\u00ed (iPrEx, PROUD, Partners PrEP)<\/strong>. Manufactured by Emcure Pharmaceuticals. Specialist-supervised; requires HIV-negative status confirmed before starting and every 3 months on therapy.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f6f7fb;border:1px solid #e3e5ee;border-radius:8px;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.55;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> Dod\u00e1v\u00e1no od v\u00fdrobce certifikovan\u00e9ho WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 <a href=\"\/cs\/reviews\/\" rel=\"noopener\">1 400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Objedn\u00e1v\u00e1n\u00ed z MedsBase v\u00e1m zaji\u0161\u0165uje dod\u00e1vky od v\u00fdrobce certifikovan\u00e9ho WHO-GMP, diskr\u00e9tn\u00ed balen\u00ed v oby\u010dejn\u00e9 ob\u00e1lce, celosv\u011btovou dopravu a hodnocen\u00ed 4,9\u2605 od v\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch z\u00e1kazn\u00edk\u016f. Platby kartou jsou sm\u011brov\u00e1ny p\u0159es regulovan\u00fd krypto-on-ramp \u2014 popis na v\u00fdpisu z va\u0161eho bankovn\u00edho \u00fa\u010dtu bude obsahovat jm\u00e9no procesoru (regulovan\u00e9ho procesoru plateb kartou), nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku. Ka\u017ed\u00e1 z\u00e1silka je pokryta na\u0161\u00edm <a href=\"\/cs\/medsbase-re-shipment-assurance-policy\/\" rel=\"noopener\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.<\/p>\n<p><strong>Tavin EM<\/strong> je <strong>denn\u00ed profylaxe p\u0159ed expozic\u00ed HIV (PrEP)<\/strong> tabletka kombinuj\u00edc\u00ed <strong>tenofovir disoproxil fumar\u00e1t 300 mg<\/strong> a <strong>emtricitabine 200 mg<\/strong> &mdash; the same two antiretroviral molecules that make up the brand-name Truvada&reg; originally developed by Gilead Sciences. Manufactured by Emcure Pharmaceuticals &mdash; an Indian antiretroviral specialist with extensive HIV-medication portfolio and global tender supply relationships.<\/p>\n<p>P\u0159i pravideln\u00e9m u\u017e\u00edv\u00e1n\u00ed HIV-negativn\u00edmi dosp\u011bl\u00fdmi s v\u00fdznamn\u00fdm rizikem expozice sni\u017euje PrEP zalo\u017een\u00fd na TDF\/FTC riziko n\u00e1kazy HIV-1 o <strong>v\u00edce ne\u017e 99 %<\/strong> (iPrEx open-label extension, PROUD, Partners PrEP). Vynech\u00e1n\u00ed v\u00edce ne\u017e jedn\u00e9 nebo dvou d\u00e1vek t\u00fddn\u011b v\u00fdrazn\u011b sni\u017euje ochranu, proto je PrEP v z\u00e1sad\u011b <strong>intervence v adherenci<\/strong> stejn\u011b jako farmakologick\u00fd z\u00e1sah.<\/p>\n<h2 class=\"wp-block-heading\">What Is Tavin EM?<\/h2>\n<p>Tavin EM is a fixed-dose combination tablet of two nucleoside reverse transcriptase inhibitors (NRTIs):<\/p>\n<ul>\n<li><strong>Tenofovir disoproxil fumar\u00e1t (TDF) 300 mg<\/strong> \u2014 blokuje reverzn\u00ed transkript\u00e1zu HIV, \u010d\u00edm\u017e zabra\u0148uje viru v integraci do hostitelsk\u00e9 DNA<\/li>\n<li><strong>Emtricitabin (FTC) 200 mg<\/strong> \u2014 analog cytidinu, kter\u00fd rovn\u011b\u017e inhibuje reverzn\u00ed transkript\u00e1zu, s komplement\u00e1rn\u00edm profilem rezistence v\u016f\u010di TDF<\/li>\n<\/ul>\n<p>Pou\u017e\u00edv\u00e1 se jako <strong>PrEP<\/strong>, oba l\u00e9ky p\u0159edem napl\u0148uj\u00ed HIV-negativn\u00ed bu\u0148ky inhibitorem, tak\u017ee jak\u00fdkoli p\u0159ich\u00e1zej\u00edc\u00ed virus ze sexu\u00e1ln\u00edho nebo injek\u010dn\u00edho kontaktu nen\u00ed schopen vytvo\u0159it produktivn\u00ed infekci. Kombinace je tak\u00e9 schv\u00e1lena pro l\u00e9\u010dbu HIV-1 (jako sou\u010d\u00e1st t\u0159\u00edl\u00e9\u010debn\u00e9ho re\u017eimu) a pro chronickou hepatitidu B, i kdy\u017e tato str\u00e1nka se zam\u011b\u0159uje na pou\u017eit\u00ed v PrEP.<\/p>\n<p><strong>Klinick\u00e1 ekvivalence:<\/strong> Tavin EM, branded Truvada, Tenvir-EM, Tenof-EM, Tavin-EM, and Ricovir-EM all contain the same fixed-dose combination of TDF 300 mg + FTC 200 mg. Bioequivalence between manufacturers is established by drug-regulatory bodies through pharmacokinetic equivalence testing. The choice between them is primarily about manufacturer, supply, and cost &mdash; not clinical outcome.<\/p>\n<h2 class=\"wp-block-heading\">How Tavin EM Works as PrEP<\/h2>\n<p>P\u0159i denn\u00edm u\u017e\u00edv\u00e1n\u00ed dosahuj\u00ed tenofovir a emtricitabin stabiln\u00ed koncentrace v krvi, genit\u00e1ln\u00ed sliznici a rekt\u00e1ln\u00ed tk\u00e1ni. Kdy\u017e dojde k expozici HIV \u2014 p\u0159i nechr\u00e1n\u011bn\u00e9m sexu, sd\u00edlen\u00ed injek\u010dn\u00edho vybaven\u00ed nebo slizni\u010dn\u00edm kontaktu s infikovan\u00fdmi tekutinami \u2014 l\u00e9k je ji\u017e p\u0159\u00edtomen uvnit\u0159 neinfikovan\u00fdch bun\u011bk a blokuje krok reverzn\u00ed transkript\u00e1zy viru d\u0159\u00edve, ne\u017e m\u016f\u017ee integrovat do hostitelsk\u00e9 DNA a vytvo\u0159it chronickou infekci.<\/p>\n<p>Kl\u00ed\u010dov\u00e9 farmakokinetick\u00e9 body ovliv\u0148uj\u00edc\u00ed ochranu:<\/p>\n<ul>\n<li><strong>Koncentrace v rekt\u00e1ln\u00ed tk\u00e1ni<\/strong> dosahuje ochrann\u00fdch hladin p\u0159ibli\u017en\u011b po <strong>7 dnech<\/strong> denn\u00edho d\u00e1vkov\u00e1n\u00ed. Proto je denn\u00ed PrEP rychle \u00fa\u010dinn\u00fd pro mu\u017ee, kte\u0159\u00ed maj\u00ed sex s mu\u017ei<\/li>\n<li><strong>Koncentrace v cervikovagin\u00e1ln\u00ed tk\u00e1ni<\/strong> dosahuje ochrann\u00fdch hladin pomaleji \u2014 p\u0159ibli\u017en\u011b <strong>20\u201321 dn\u016f<\/strong> denn\u00edho u\u017e\u00edv\u00e1n\u00ed. \u017deny, transgender mu\u017ei a kdokoli s vagin\u00e1ln\u00edm nebo front\u00e1ln\u00edm sexem pot\u0159ebuj\u00ed del\u0161\u00ed dodr\u017eov\u00e1n\u00ed p\u0159ed plnou ochranou<\/li>\n<li><strong>Tenofovir m\u00e1 dlouh\u00fd intracelul\u00e1rn\u00ed polo\u010das<\/strong> \u2014 p\u0159ibli\u017en\u011b 4\u20135 dn\u00ed. Vynech\u00e1n\u00ed jedn\u00e9 d\u00e1vky okam\u017eit\u011b nezru\u0161\u00ed ochranu, ale vynech\u00e1n\u00ed v\u00edce d\u00e1vek t\u00fddn\u011b ano<\/li>\n<li><strong>Kryt\u00ed ocasu<\/strong> po ukon\u010den\u00ed expozice: pokra\u010dujte v u\u017e\u00edv\u00e1n\u00ed alespo\u0148 28 dn\u00ed po posledn\u00ed potenci\u00e1ln\u00ed expozici HIV, aby bylo pokryto inkuba\u010dn\u00ed obdob\u00ed<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">P\u0159ed zah\u00e1jen\u00edm PrEP \u2013 povinn\u00e9 testy<\/h2>\n<p><strong>PrEP vy\u017eaduje potvrzen\u00fd HIV-negativn\u00ed status pod odborn\u00fdm dohledem.<\/strong> P\u0159ed prvn\u00ed d\u00e1vkou jsou povinn\u00e9 n\u00e1sleduj\u00edc\u00ed z\u00e1kladn\u00ed testy. Zah\u00e1jen\u00ed PrEP bez potvrzen\u00ed HIV-negativn\u00edho stavu m\u016f\u017ee v\u00e9st k rozvoji rezistence HIV na l\u00e9ky, pokud jste ji\u017e infikov\u00e1ni \u2013 s d\u016fsledky pro va\u0161e budouc\u00ed mo\u017enosti l\u00e9\u010dby.<\/p>\n<table>\n<thead>\n<tr>\n<th>Test<\/th>\n<th>Pro\u010d je to d\u016fle\u017eit\u00e9<\/th>\n<th>Na\u010dasov\u00e1n\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>HIV test (4. generace antigen\/protil\u00e1tka nebo HIV RNA)<\/strong><\/td>\n<td>Mus\u00ed b\u00fdt potvrzen jako negativn\u00ed. Pokud jste HIV-pozitivn\u00ed a dostanete PrEP, dvoul\u00e9\u010debn\u00fd re\u017eim je sub-terapeutick\u00fd a selektuje mutace rezistence HIV (M184V, K65R)<\/td>\n<td>Do 7 dn\u016f od zah\u00e1jen\u00ed<\/td>\n<\/tr>\n<tr>\n<td><strong>Povrchov\u00fd protil\u00e1tkov\u00fd test proti hepatitid\u011b B (anti-HBs)<\/strong><\/td>\n<td>Tenofovir\/emtricitabin tak\u00e9 l\u00e9\u010d\u00ed HBV. U pacient\u016f s HBV-pozitivitou m\u016f\u017ee ukon\u010den\u00ed PrEP zp\u016fsobit z\u00e1va\u017en\u00e9 vzplanut\u00ed hepatitidy. Pacienti s HBV-pozitivitou vy\u017eaduj\u00ed zapojen\u00ed hepatologa.<\/td>\n<td>V\u00fdchoz\u00ed hodnota<\/td>\n<\/tr>\n<tr>\n<td><strong>Ren\u00e1ln\u00ed funkce (kreatinin, eGFR)<\/strong><\/td>\n<td>TDF se vylu\u010duje ledvinami a m\u016f\u017ee zp\u016fsobit d\u00e1vkov\u011b z\u00e1vislou ren\u00e1ln\u00ed toxicitu. eGFR &lt;60 ml\/min je obvykle kontraindikac\u00ed pro PrEP zalo\u017een\u00fd na TDF (m\u00edsto toho zva\u017ete alternativy zalo\u017een\u00e9 na TAF)<\/td>\n<td>V\u00fdchoz\u00ed hodnota, pot\u00e9 ka\u017ed\u00fdch 6 m\u011bs\u00edc\u016f<\/td>\n<\/tr>\n<tr>\n<td><strong>Test na pohlavn\u011b p\u0159enosn\u00e9 infekce (syfilis, chlamydie, kapavka)<\/strong><\/td>\n<td>PrEP zabra\u0148uje infekci HIV, nikoli jin\u00fdm pohlavn\u011b p\u0159enosn\u00fdm infekc\u00edm. V\u00fdchoz\u00ed vy\u0161et\u0159en\u00ed a \u010dtvrtletn\u00ed screening jsou standardem p\u00e9\u010de<\/td>\n<td>V\u00fdchoz\u00ed hodnota, ka\u017ed\u00e9 3 m\u011bs\u00edce<\/td>\n<\/tr>\n<tr>\n<td><strong>T\u011bhotensk\u00fd test (pokud je to relevantn\u00ed)<\/strong><\/td>\n<td>TDF\/FTC je kategorie B a je pova\u017eov\u00e1n za bezpe\u010dn\u00fd v t\u011bhotenstv\u00ed, ale dokumentace je d\u016fle\u017eit\u00e1<\/td>\n<td>V\u00fdchoz\u00ed hodnota<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>\u010casov\u00fd pl\u00e1n opakovan\u00e9ho testov\u00e1n\u00ed:<\/strong> Test na HIV se opakuje ka\u017ed\u00e9 3 m\u011bs\u00edce b\u011bhem u\u017e\u00edv\u00e1n\u00ed PrEP. Funkce ledvin se vy\u0161et\u0159uje ka\u017ed\u00fdch 6 m\u011bs\u00edc\u016f. Test na pohlavn\u011b p\u0159enosn\u00e9 infekce ka\u017ed\u00e9 3 m\u011bs\u00edce. Jak\u00e1koli odchylka od normy m\u016f\u017ee vy\u017eadovat p\u0159eru\u0161en\u00ed PrEP.<\/p>\n<h2 class=\"wp-block-heading\">Mo\u017enosti d\u00e1vkov\u00e1n\u00ed<\/h2>\n<table>\n<thead>\n<tr>\n<th>Protokol<\/th>\n<th>Pro koho je ur\u010den<\/th>\n<th>Re\u017eim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Denn\u00ed PrEP<\/strong> (prvn\u00ed volba)<\/td>\n<td>V\u0161ichni dosp\u011bl\u00ed v riziku: cisgender mu\u017ei, cisgender \u017eeny, transgender osoby, u\u017eivatel\u00e9 injek\u010dn\u00edch drog<\/td>\n<td>1 tableta denn\u011b, u\u017e\u00edvan\u00e1 ve stejnou dobu ka\u017ed\u00fd den<\/td>\n<\/tr>\n<tr>\n<td><strong>Ud\u00e1lostmi \u0159\u00edzen\u00e9 \/ 2-1-1 (\u201cna vy\u017e\u00e1d\u00e1n\u00ed\u201d)<\/strong> d\u00e1vkov\u00e1n\u00ed<\/td>\n<td><strong>Pouze pro cisgender MSM<\/strong> \u2014 siln\u00e9 d\u016fkazy z studi\u00ed IPERGAY a Prevenir. NEDOPORU\u010cUJE se pro cisgender \u017eeny, transgender \u017eeny nebo kohokoli s vagin\u00e1ln\u00edm\/front\u00e1ln\u00edm sexem, proto\u017ee koncentrace l\u00e9ku ve vagin\u00e1ln\u00ed\/rekt\u00e1ln\u00ed tk\u00e1ni se li\u0161\u00ed<\/td>\n<td>2 tablety 2\u201324 hodin p\u0159ed sexem, 1 tableta 24 hodin po prvn\u00ed dvojici, 1 tableta 48 hodin po prvn\u00ed dvojici. P\u0159i pokra\u010duj\u00edc\u00ed expozici pokra\u010dujte 1 tabletou denn\u011b a\u017e 2 dny po posledn\u00ed sexu\u00e1ln\u00ed expozici<\/td>\n<\/tr>\n<tr>\n<td><strong>Postupn\u00e9 denn\u00ed navy\u0161ov\u00e1n\u00ed<\/strong> (ochrann\u00e9 hladiny)<\/td>\n<td>Mu\u017ei praktikuj\u00edc\u00ed receptivn\u00ed an\u00e1ln\u00ed sex<\/td>\n<td>~7 dn\u016f denn\u00edho u\u017e\u00edv\u00e1n\u00ed k dosa\u017een\u00ed ochrann\u00fdch koncentrac\u00ed v rekt\u00e1ln\u00ed tk\u00e1ni<\/td>\n<\/tr>\n<tr>\n<td><strong>Postupn\u00e9 denn\u00ed navy\u0161ov\u00e1n\u00ed<\/strong> (ochrann\u00e9 hladiny, vagin\u00e1ln\u00ed)<\/td>\n<td>\u017deny, transgender mu\u017ei maj\u00edc\u00ed vagin\u00e1ln\u00ed\/front\u00e1ln\u00ed sex<\/td>\n<td>~21 dn\u016f denn\u00edho u\u017e\u00edv\u00e1n\u00ed k dosa\u017een\u00ed ochrann\u00fdch koncentrac\u00ed v cervikovagin\u00e1ln\u00ed tk\u00e1ni. Nedodr\u017een\u00ed tohoto prahu v\u00fdrazn\u011b sni\u017euje \u00fa\u010dinnost<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Kl\u00ed\u010dov\u00e1 klinick\u00e1 nuance:<\/strong> PrEP je <strong>nen\u00ed okam\u017eit\u00e1 ochrana<\/strong>. Denn\u00ed d\u00e1vkov\u00e1n\u00ed mus\u00ed b\u00fdt u\u017e\u00edv\u00e1no pravideln\u011b a \u010das pot\u0159ebn\u00fd k ochran\u011b z\u00e1vis\u00ed na tk\u00e1\u0148ov\u00e9m odd\u00edlu (rychlej\u0161\u00ed pro rekt\u00e1ln\u00ed tk\u00e1\u0148 ne\u017e pro cervikovagin\u00e1ln\u00ed). Vynech\u00e1n\u00ed v\u00edce ne\u017e 1\u20132 d\u00e1vek t\u00fddn\u011b v\u00fdrazn\u011b sni\u017euje \u00fa\u010dinnost.<\/p>\n<h2 class=\"wp-block-heading\">Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n<p>V\u011bt\u0161ina vedlej\u0161\u00edch \u00fa\u010dink\u016f se objevuje v prvn\u00edch 2\u20134 t\u00fddnech (\u201cstart-up syndrom\u201d) a s pokra\u010duj\u00edc\u00edm u\u017e\u00edv\u00e1n\u00edm vymiz\u00ed.<\/p>\n<table>\n<thead>\n<tr>\n<th>Z\u00e1va\u017enost<\/th>\n<th>Vedlej\u0161\u00ed \u00fa\u010dinek<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>B\u011b\u017en\u00e9, p\u0159echodn\u00e9 (prvn\u00ed 2\u20134 t\u00fddny)<\/strong><\/td>\n<td>Nevolnost, pr\u016fjem, b\u0159i\u0161n\u00ed diskomfort, bolest hlavy, \u00fanava. Obvykle vymiz\u00ed bez z\u00e1sahu<\/td>\n<\/tr>\n<tr>\n<td><strong>M\u00e9n\u011b \u010dast\u00e9<\/strong><\/td>\n<td>Z\u00e1vrat\u011b, vyr\u00e1\u017eka, sn\u00ed\u017een\u00e1 chu\u0165 k j\u00eddlu, \u00fabytek hmotnosti, nespavost<\/td>\n<\/tr>\n<tr>\n<td><strong>D\u00e1vkov\u011b z\u00e1visl\u00e9 (dlouhodob\u00e9 sledov\u00e1n\u00ed)<\/strong><\/td>\n<td>M\u00edrn\u00e9 sn\u00ed\u017een\u00ed miner\u00e1ln\u00ed hustoty kost\u00ed (reverzibiln\u00ed po vysazen\u00ed), mal\u00fd pokles ren\u00e1ln\u00ed funkce (reverzibiln\u00ed u v\u011bt\u0161iny mu\u017e\u016f)<\/td>\n<\/tr>\n<tr>\n<td><strong>Vz\u00e1cn\u00e9, ale z\u00e1va\u017en\u00e9<\/strong><\/td>\n<td>Akutn\u00ed selh\u00e1n\u00ed ledvin (Fanconiho syndrom), lakt\u00e1tov\u00e1 acid\u00f3za, v\u00fdrazn\u00e9 zv\u00fd\u0161en\u00ed jatern\u00edch enzym\u016f, jatern\u00ed steat\u00f3za. P\u0159i t\u011b\u017ek\u00e9 \u00fanav\u011b, nevysv\u011btliteln\u00e9 bolesti sval\u016f, p\u0159etrv\u00e1vaj\u00edc\u00ed nevolnosti nebo \u017eloutence vyhledejte neodkladnou l\u00e9ka\u0159skou pomoc<\/td>\n<\/tr>\n<tr>\n<td><strong>Specifick\u00e9 pro HBV (pokud je HBV-pozitivn\u00ed)<\/strong><\/td>\n<td>P\u0159eru\u0161en\u00ed l\u00e9\u010dby TDF\/FTC u pacienta s HBV m\u016f\u017ee vyvolat akutn\u00ed hepatitidu \u2014 potenci\u00e1ln\u011b \u017eivot ohro\u017euj\u00edc\u00ed stav. Pacienti s HBV na PrEP <strong>nesm\u011bj\u00ed n\u00e1hle p\u0159estat<\/strong> bez konzultace s hepatologem<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Kontraindikace a preventivn\u00ed opat\u0159en\u00ed<\/h2>\n<ul>\n<li><strong>Prok\u00e1zan\u00fd HIV pozitivn\u00ed status<\/strong> \u2014 TDF\/FTC je dvoul\u00e9\u010debn\u00fd re\u017eim, kter\u00fd je sub-terapeutick\u00fd pro l\u00e9\u010dbu HIV; jeho pou\u017e\u00edv\u00e1n\u00ed vede k rezisten\u010dn\u00edm mutac\u00edm, kter\u00e9 ohro\u017euj\u00ed budouc\u00ed l\u00e9\u010dbu<\/li>\n<li><strong>T\u011b\u017ek\u00e9 po\u0161kozen\u00ed ledvin (eGFR &lt;60 ml\/min)<\/strong> \u2014 TDF vy\u017eaduje funk\u010dn\u00ed ledviny; alternativou pro eGFR 30\u201359 je PrEP na b\u00e1zi TAF<\/li>\n<li><strong>Sou\u010dasn\u00e9 u\u017e\u00edv\u00e1n\u00ed nefrotoxick\u00fdch l\u00e9k\u016f<\/strong> \u2014 aminoglykosidy, vysok\u00e9 d\u00e1vky NSAID, intraven\u00f3zn\u00ed kontrast, adefovir, cidofovir. P\u0159ed kombinac\u00ed konzultujte s l\u00e9ka\u0159em<\/li>\n<li><strong>Akutn\u00ed hepatitida<\/strong> \u2014 bu\u010fte opatrn\u00ed a konzultujte hepatologa<\/li>\n<li><strong>Kojen\u00ed<\/strong> \u2014 tenofovir se vylu\u010duje do mate\u0159sk\u00e9ho ml\u00e9ka. Posouzen\u00ed rizika a p\u0159\u00ednos\u016f s klinick\u00fdm l\u00e9ka\u0159em se doporu\u010duje, pokud je d\u00edt\u011b HIV-negativn\u00ed a existuj\u00ed dal\u0161\u00ed mo\u017enosti prevence HIV<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<ul>\n<li><strong>Nefrotoxick\u00e9 l\u00e9ky<\/strong> (aminoglykosidy, amfotericin B, cidofovir, intraven\u00f3zn\u00ed pentamidin, vysok\u00e9 d\u00e1vky nebo chronick\u00e9 NSAID) \u2014 aditivn\u00ed nefrotoxicita<\/li>\n<li><strong>Didanosin (ddI)<\/strong> \u2014 zv\u00fd\u0161en\u00e1 expozice didanosinu a toxicita; kombinaci se vyhn\u011bte<\/li>\n<li><strong>Ledipasvir\/sofosbuvir (Harvoni)<\/strong> \u2014 zvy\u0161uje expozici tenofoviru. Obecn\u011b zvl\u00e1dnuteln\u00e9 s monitorov\u00e1n\u00edm ledvin, ale doporu\u010duje se konzultace s l\u00e9ka\u0159em<\/li>\n<li><strong>Adefovir<\/strong> \u2014 stejn\u00e1 t\u0159\u00edda l\u00e9\u010div, nekombinujte<\/li>\n<li><strong>HIV postexpozi\u010dn\u00ed profylaxe (PEP) re\u017eimy<\/strong> \u2014 pokud je PEP p\u0159edeps\u00e1na po vysoce rizikov\u00e9 expozici b\u011bhem u\u017e\u00edv\u00e1n\u00ed PrEP, re\u017eimy jsou spole\u010dn\u011b \u0159\u00edzeny specialistou na HIV<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Jak u\u017e\u00edvat \u2014 praktick\u00e9 pokyny<\/h2>\n<ul>\n<li>Tabletu spolkn\u011bte celou s vodou, <strong>ve stejnou dobu ka\u017ed\u00fd den<\/strong>. D\u016fslednost je to, co zaji\u0161\u0165uje \u00fa\u010dinnost PrEP \u2014 vynech\u00e1n\u00ed v\u00edce ne\u017e 1\u20132 d\u00e1vek t\u00fddn\u011b v\u00fdrazn\u011b sni\u017euje ochranu<\/li>\n<li>Lze u\u017e\u00edvat s j\u00eddlem nebo nala\u010dno. Pokud se v prvn\u00edch t\u00fddnech objev\u00ed nevolnost, u\u017e\u00edv\u00e1n\u00ed s j\u00eddlem pom\u00e1h\u00e1<\/li>\n<li>Pokud je d\u00e1vka vynech\u00e1na a vzpomenete si na ni do 24 hodin, vezm\u011bte ji co nejd\u0159\u00edve. Pokud uplynulo v\u00edce ne\u017e 24 hodin, vynechanou d\u00e1vku p\u0159esko\u010dte a pokra\u010dujte podle pl\u00e1nu \u2014 ned\u00e1vejte dvojitou d\u00e1vku<\/li>\n<li>Nep\u0159est\u00e1vejte n\u00e1hle u\u017e\u00edvat PrEP, pokud jste HBV-pozitivn\u00ed \u2014 nejprve kontaktujte sv\u00e9ho l\u00e9ka\u0159e<\/li>\n<li>Po posledn\u00ed sexu\u00e1ln\u00ed expozici pokra\u010dujte v u\u017e\u00edv\u00e1n\u00ed PrEP alespo\u0148 28 dn\u00ed (2-d\u00e1vkov\u00fd ochrann\u00fd interval), aby byla pokryta p\u0159\u00edpadn\u00e1 inkuba\u010dn\u00ed doba viru<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Skladov\u00e1n\u00ed<\/h2>\n<ul>\n<li>Skladujte p\u0159i teplot\u011b do 30\u00b0C na such\u00e9m a chladn\u00e9m m\u00edst\u011b<\/li>\n<li>Uchov\u00e1vejte v p\u016fvodn\u00edm blistru a\u017e do pou\u017eit\u00ed<\/li>\n<li>Nepou\u017e\u00edvejte po datu expirace uveden\u00e9m na obalu<\/li>\n<li>Uchov\u00e1vejte mimo dosah d\u011bt\u00ed a dom\u00e1c\u00edch zv\u00ed\u0159at<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Tavin EM vs Branded Truvada, TAF-based PrEP, and Other Generics<\/h2>\n<table>\n<thead>\n<tr>\n<th>Mo\u017enost<\/th>\n<th>Slo\u017een\u00ed<\/th>\n<th>Bezpe\u010dnost pro ledviny\/kosti<\/th>\n<th>\u00dadaje o \u00fa\u010dinnosti podle pohlav\u00ed<\/th>\n<th>Cenov\u00e1 \u00farove\u0148<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Tavin EM<\/strong> (tento produkt)<\/td>\n<td>TDF 300 + FTC 200<\/td>\n<td>Standardn\u00ed monitorov\u00e1n\u00ed TDF<\/td>\n<td>V\u0161echny expozice (vagin\u00e1ln\u00ed + an\u00e1ln\u00ed + injek\u010dn\u00ed)<\/td>\n<td>Nejni\u017e\u0161\u00ed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/medsbase.com\/cs\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a> (Cipla)<\/td>\n<td>TDF 300 + FTC 200<\/td>\n<td>Standardn\u00ed monitorov\u00e1n\u00ed TDF<\/td>\n<td>V\u0161echny expozice<\/td>\n<td>N\u00edzk\u00e1<\/td>\n<\/tr>\n<tr>\n<td>Origin\u00e1ln\u00ed Truvada\u00ae (Gilead)<\/td>\n<td>TDF 300 + FTC 200<\/td>\n<td>Standardn\u00ed monitorov\u00e1n\u00ed TDF<\/td>\n<td>V\u0161echny expozice<\/td>\n<td>Nejvy\u0161\u0161\u00ed<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/medsbase.com\/cs\/tenvir-af\/\" rel=\"noopener\">Tenvir AF<\/a> \/ Descovy\u00ae<\/td>\n<td>TAF 25 + FTC 200<\/td>\n<td>V\u00fdrazn\u011b \u0161etrn\u011bj\u0161\u00ed k ledvin\u00e1m a kostn\u00ed denzit\u011b<\/td>\n<td>Schv\u00e1leno pouze pro MSM a transgender \u017eeny \u2013 \u00fadaje pro cis-\u017eeny ne\u00fapln\u00e9<\/td>\n<td>St\u0159edn\u00ed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Kter\u00fd si vybrat?<\/strong> Pokud m\u00e1te norm\u00e1ln\u00ed funkci ledvin a \u017e\u00e1dn\u00e9 probl\u00e9my s hustotou kost\u00ed, je TDF\/FTC (produkt na t\u00e9to str\u00e1nce) prvn\u00ed volbou podle v\u0161ech hlavn\u00edch sm\u011brnic (CDC, WHO, BHIVA, IAS-USA). Pokud m\u00e1te eGFR 30\u201359 ml\/min, osteopor\u00f3zu nebo jin\u00e9 d\u016fvody k vyhnut\u00ed se TDF, je PrEP na b\u00e1zi TAF (Tenvir AF \/ Descovy) bezpe\u010dn\u011bj\u0161\u00ed, ale schv\u00e1len\u00fd pouze pro expozici HIV p\u0159i an\u00e1ln\u00edm sexu. Proberte svou konkr\u00e9tn\u00ed situaci s l\u00e9ka\u0159em p\u0159edepisuj\u00edc\u00edm l\u00e9\u010dbu HIV.<\/p>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed mo\u017enosti PrEP<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tenvir-em\/\" rel=\"noopener\"><strong>Tenvir EM<\/strong><\/a> \u2014 generikum Truvada od Cipla (nejv\u011bt\u0161\u00ed indick\u00fd v\u00fdrobce, p\u0159edkvalifikovan\u00fd WHO)<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tenvir-af\/\" rel=\"noopener\"><strong>Tenvir AF<\/strong><\/a> \u2014 generikum Descovy od Cipla (na b\u00e1zi TAF, \u0161etrn\u011bj\u0161\u00ed k ledvin\u00e1m a kostem)<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/ricovir-em\/\" rel=\"noopener\"><strong>Ricovir EM<\/strong><\/a> \u2014 generikum Truvada od Mylan<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/tenof-em\/\" rel=\"noopener\"><strong>Tenof EM<\/strong><\/a> \u2014 generikum Truvada od spole\u010dnosti Hetero<\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/std-protection-pack\/\" rel=\"noopener\"><strong>Bal\u00ed\u010dek ochrany proti STD<\/strong><\/a> \u2014 kombinace TDF\/FTC + doxycyklin + azithromycin pro sexu\u00e1ln\u00ed zdrav\u00ed<\/li>\n<\/ul>\n<p>Viz tak\u00e9: <a href=\"\/cs\/tenvir-em\/\">komplexn\u00ed str\u00e1nka Tenvir EM<\/a> (n\u00e1\u0161 nej\u010dast\u011bji doporu\u010dovan\u00fd produkt TDF\/FTC) a \u0161ir\u0161\u00ed <a href=\"\/cs\/hiv-medication\/\">L\u00e9ky na HIV<\/a> a <a href=\"\/cs\/sexual-health\/\">Sexu\u00e1ln\u00ed zdrav\u00ed<\/a> kategorie.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">Is Tavin EM the same as Truvada?<\/h3>\n<p>Clinically equivalent. Tavin EM contains exactly the same active ingredients as Truvada (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg) and is produced to pharmaceutical bioequivalence standards. The clinical evidence supporting PrEP is based on these two molecules, so the protection delivered by a bioequivalent generic is the same as the original brand.<\/p>\n<h3 class=\"wp-block-heading\">How effective is Tavin EM at preventing HIV?<\/h3>\n<p>PrEP na b\u00e1zi TDF\/FTC sni\u017euje riziko n\u00e1kazy HIV-1 o <strong>v\u00edce ne\u017e 99 %<\/strong> u lid\u00ed, kte\u0159\u00ed dodr\u017euj\u00ed vysokou adherenci (alespo\u0148 4 d\u00e1vky t\u00fddn\u011b u mu\u017e\u016f, kte\u0159\u00ed maj\u00ed sex s mu\u017ei; denn\u00ed d\u00e1vkov\u00e1n\u00ed u cisgender \u017een a trans mu\u017e\u016f). Nejvy\u0161\u0161\u00ed kvalitu d\u016fkaz\u016f poskytuj\u00ed randomizovan\u00e9 kontrolovan\u00e9 studie iPrEx, PROUD a Partners PrEP.<\/p>\n<h3 class=\"wp-block-heading\">Jak dlouho trv\u00e1, ne\u017e se dostav\u00ed ochrana?<\/h3>\n<p>Z\u00e1le\u017e\u00ed na zp\u016fsobu expozice. P\u0159i rekt\u00e1ln\u00ed expozici HIV (an\u00e1ln\u00ed sex) dos\u00e1hne denn\u00ed d\u00e1vkov\u00e1n\u00ed ochrann\u00e9 hladiny v tk\u00e1n\u00edch p\u0159ibli\u017en\u011b za <strong>7 dnech<\/strong>. P\u0159i cervikovagin\u00e1ln\u00ed expozici (vagin\u00e1ln\u00ed\/\u010deln\u00ed sex) je pot\u0159eba p\u0159ibli\u017en\u011b <strong>20\u201321 dn\u016f<\/strong> denn\u00edho d\u00e1vkov\u00e1n\u00ed. U protokolu 2-1-1 na vy\u017e\u00e1d\u00e1n\u00ed (pouze pro cisgender mu\u017ee, kte\u0159\u00ed maj\u00ed sex s mu\u017ei) poskytuje prvn\u00ed dvojit\u00e1 d\u00e1vka akutn\u00ed farmakologickou ochranu.<\/p>\n<h3 class=\"wp-block-heading\">Mus\u00edm p\u0159ed za\u010d\u00e1tkem u\u017e\u00edv\u00e1n\u00ed nav\u0161t\u00edvit l\u00e9ka\u0159e?<\/h3>\n<p><strong>Ano.<\/strong> PrEP vy\u017eaduje potvrzen\u00fd HIV-negativn\u00ed status pod odborn\u00fdm dohledem p\u0159ed zah\u00e1jen\u00edm. Zah\u00e1jen\u00ed PrEP p\u0159i nev\u011bdom\u00e9 HIV-pozitivit\u011b m\u016f\u017ee zp\u016fsobit rezistenci na l\u00e9ky, kter\u00e1 omezuje budouc\u00ed l\u00e9\u010dbu HIV. D\u00e1le je nutn\u00e9 z\u00e1kladn\u00ed vy\u0161et\u0159en\u00ed funkce ledvin, HBV a testy na pohlavn\u011b p\u0159enosn\u00e9 infekce. Ka\u017ed\u00e9 3 m\u011bs\u00edce je t\u0159eba opakovat screening na HIV a pohlavn\u011b p\u0159enosn\u00e9 infekce; ka\u017ed\u00fdch 6 m\u011bs\u00edc\u016f vy\u0161et\u0159en\u00ed funkce ledvin.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Tavin EM only when I think I&#8217;ll need it?<\/h3>\n<p>Pro <strong>cisgender mu\u017ei, kte\u0159\u00ed maj\u00ed sex s mu\u017ei<\/strong>, protokol \u201c2-1-1\u201d (na z\u00e1klad\u011b ud\u00e1losti) m\u00e1 siln\u00e9 d\u016fkazy z klinick\u00fdch studi\u00ed (IPERGAY, Prevenir). Pro <strong>cisgender \u017eeny, transgender \u017eeny a kohokoli s vagin\u00e1ln\u00edm\/\u010deln\u00edm sexem<\/strong>, d\u00e1vkov\u00e1n\u00ed na vy\u017e\u00e1d\u00e1n\u00ed je <strong>nedoporu\u010duje se<\/strong> \u2014 farmakokinetika v tk\u00e1n\u00edch se li\u0161\u00ed a pro spolehlivou ochranu je nutn\u00e9 denn\u00ed d\u00e1vkov\u00e1n\u00ed.<\/p>\n<h3 class=\"wp-block-heading\">Co se stane, pokud ho p\u0159estanu u\u017e\u00edvat?<\/h3>\n<p>Pokud jste HIV-negativn\u00ed a HBV-negativn\u00ed, m\u016f\u017eete bezpe\u010dn\u011b p\u0159estat po dokon\u010den\u00ed <strong>28denn\u00ed ocas<\/strong> po va\u0161\u00ed posledn\u00ed expozici HIV. Pokud jste HBV-pozitivn\u00ed, <strong>nep\u0159est\u00e1vejte bez \u00fa\u010dasti l\u00e9ka\u0159e<\/strong> \u2014 n\u00e1hl\u00e9 ukon\u010den\u00ed TDF u chronick\u00e9 HBV m\u016f\u017ee vyvolat akutn\u00ed vzplanut\u00ed hepatitidy.<\/p>\n<h3 class=\"wp-block-heading\">Chr\u00e1n\u00ed m\u011b PrEP p\u0159ed dal\u0161\u00edmi pohlavn\u011b p\u0159enosn\u00fdmi nemocemi?<\/h3>\n<p><strong>Ne.<\/strong> PrEP chr\u00e1n\u00ed pouze p\u0159ed HIV. St\u00e1le pot\u0159ebujete kondomy, o\u010dkov\u00e1n\u00ed (HPV, HepA, HepB, pokud nejste imunn\u00ed) a \u010dtvrtletn\u00ed screening na chlamydie, kapavku a syfilis. Nav\u0161tivte na\u0161e <a href=\"\/cs\/std-protection-pack\/\" rel=\"noopener\">Bal\u00ed\u010dek ochrany proti STD<\/a> pro \u0161ir\u0161\u00ed bal\u00ed\u010dek l\u00e9k\u016f na sexu\u00e1ln\u00ed zdrav\u00ed v\u010detn\u011b DoxyPEP.<\/p>\n<h3 class=\"wp-block-heading\">Does Tavin EM have side effects?<\/h3>\n<p>V\u011bt\u0161ina mu\u017e\u016f poci\u0165uje v prvn\u00edch 2\u20134 t\u00fddnech m\u00edrnou nevolnost, bolest hlavy nebo pr\u016fjem (\u201cstart-up syndrom\u201d), kter\u00e9 s pokra\u010duj\u00edc\u00edm u\u017e\u00edv\u00e1n\u00edm vymiz\u00ed. Dlouhodob\u011b TDF zp\u016fsobuje m\u00edrn\u00fd pokles hustoty kostn\u00edho miner\u00e1lu a nepatrn\u00e9 zhor\u0161en\u00ed ren\u00e1ln\u00ed funkce \u2014 oboj\u00ed je obvykle reverzibiln\u00ed po vysazen\u00ed. Z\u00e1va\u017en\u00e1 ren\u00e1ln\u00ed toxicita (Fanconiho syndrom, akutn\u00ed selh\u00e1n\u00ed ledvin) je vz\u00e1cn\u00e1, ale vy\u017eaduje neodkladnou l\u00e9ka\u0159skou pomoc.<\/p>\n<h3 class=\"wp-block-heading\">Can I combine Tavin EM with other medications?<\/h3>\n<p>Ano, v\u011bt\u0161ina l\u00e9k\u016f. Vyhn\u011bte se sou\u010dasn\u00e9mu u\u017e\u00edv\u00e1n\u00ed nefrotoxick\u00fdch l\u00e9k\u016f (aminoglykosidy, vysok\u00e9 d\u00e1vky NSAID, cidofovir, adefovir). V\u011bt\u0161ina b\u011b\u017en\u00fdch l\u00e9k\u016f v\u010detn\u011b hormon\u00e1ln\u00ed antikoncepce, SSRI, statin\u016f, PDE5 inhibitor\u016f a antibiotik je bezpe\u010dn\u00e1. V\u017edy informujte sv\u00e9ho p\u0159edepisuj\u00edc\u00edho l\u00e9ka\u0159e o u\u017e\u00edv\u00e1n\u00ed PrEP.<\/p>\n<h3 class=\"wp-block-heading\">Is Tavin EM available without a prescription?<\/h3>\n<p><strong>Ne.<\/strong> PrEP is a specialist-supervised regimen that requires baseline HIV-negative status confirmation, kidney-function and HBV testing, and follow-up every 3 months. Do not start PrEP without a clinician confirming HIV-negative status and baseline safety tests.<\/p>\n<h3 class=\"wp-block-heading\">Co je \u201c2-1-1\u201d on-demand protokol?<\/h3>\n<p>Ud\u00e1lostmi \u0159\u00edzen\u00fd re\u017eim studovan\u00fd v IPERGAY studii: 2 tablety u\u017eit\u00e9 2\u201324 hodin p\u0159ed o\u010dek\u00e1van\u00fdm pohlavn\u00edm stykem, 1 tableta 24 hodin po prvn\u00ed d\u00e1vce a 1 tableta 48 hodin po prvn\u00ed d\u00e1vce. Pokud pohlavn\u00ed styk pokra\u010duje, pokra\u010dujte v u\u017e\u00edv\u00e1n\u00ed 1 tablety denn\u011b a\u017e 48 hodin po posledn\u00ed expozici. D\u016fkazy podporuj\u00ed tento protokol pouze u <strong>cisgender MSM<\/strong>.<\/p>\n<p><!-- medsbase-faq-h3-converted --><\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Tavin-EM users adding bacterial-STI protection to their PrEP regimen can switch to our <a href='\/cs\/prep-starter-pack\/'>PrEP Starter Pack (Tenvir-EM + doxycyklin 100 mg)<\/a> \u2014 TDF\/FTC for HIV and doxycycline 100 mg for CDC-endorsed doxy-PEP, layered protection in one bundled order.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Those using <a href=\"https:\/\/medsbase.com\/cs\/tavin-em\/\">Tavin EM<\/a> for PrEP who wish to compare sourcing options should note that <a href=\"https:\/\/medsbase.com\/cs\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarate 300&nbsp;mg + emtricitabine 200&nbsp;mg)<\/a> contains the same WHO-approved TDF\/FTC combination and is produced to equivalent WHO-GMP quality standards by Cipla.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Pacienti u\u017e\u00edvaj\u00edc\u00ed <a href=\"https:\/\/medsbase.com\/cs\/tavin-em\/\">Tavin EM (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg)<\/a> who require an NNRTI anchor are often progressed to a complete fixed-dose combination such as <a href=\"https:\/\/medsbase.com\/cs\/avonza\/\">Avonza (TDF \/ lamivudine \/ efavirenz)<\/a>, eliminating the need for a separate third agent.<\/p>\n<p data-marker=\"mb-link-boost-taficita\" class=\"medsbase-link-boost-2026-05-25\">Oboj\u00ed <a href=\"https:\/\/medsbase.com\/cs\/tavin-em\/\">Tavin-EM<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/taficita\/\">Taficita (TAF 25&nbsp;mg + emtricitabine 200&nbsp;mg)<\/a> provide daily oral PrEP; Taficita&rsquo;s tenofovir alafenamide base is the modern choice where long-term kidney safety matters.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 id=\"related-alts\">Dal\u0161\u00ed l\u00e9ky na sexu\u00e1ln\u00ed zdrav\u00ed<\/h2>\n<ul>\n<li><a href=\"\/cs\/tenvir-em\/\">Tenvir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/ricovir-em\/\">Ricovir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/tenof-em\/\">Tenof EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/cs\/taficita\/\">Taficita (TAF\/FTC 25+200 mg, generikum Descovy)<\/a><\/li>\n<li><a href=\"\/cs\/std-protection-pack\/\">Bal\u00ed\u010dek ochrany proti STD<\/a><\/li>\n<\/ul>\n<p style=\"font-size:13px;color:#555;margin:14px 0;font-style:italic;\"><strong>Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Informace na t\u00e9to str\u00e1nce slou\u017e\u00ed pouze pro vzd\u011bl\u00e1vac\u00ed \u00fa\u010dely a nenahrazuj\u00ed l\u00e9ka\u0159skou pomoc. P\u0159ed zah\u00e1jen\u00edm, ukon\u010den\u00edm nebo zm\u011bnou jak\u00e9hokoli l\u00e9ku se v\u017edy pora\u010fte s kvalifikovan\u00fdm l\u00e9ka\u0159em.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 HIV Prevention (PrEP)<br \/>\n\u2705 Reduces risk of HIV infection<br \/>\n\u2705 Effective in high-risk populations<br \/>\n\u2705 Daily oral dose<br \/>\n\u2705 Recommended by CDC<\/p>\n<p><strong>Tavin EM<\/strong> obsahuje <strong>Emtricitabine<\/strong> a <strong>Tenofovir<\/strong>.<\/p>","protected":false},"featured_media":61729,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3304,3338,3337],"product_tag":[5819,3339,5815,5816,5354,5084,5814,3335,5670],"class_list":{"0":"post-61728","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hiv-medication","9":"product_cat-prep-medication-pre-exposure-prophylaxis","10":"product_cat-sexual-health","11":"product_tag-emcure-pharmaceuticals","12":"product_tag-emtricitabine","13":"product_tag-hiv-prevention","14":"product_tag-pre-exposure-prophylaxis","15":"product_tag-prep","16":"product_tag-tavin-em","17":"product_tag-tdf-ftc","18":"product_tag-tenofovir","19":"product_tag-truvada-generic","21":"first","22":"instock","23":"shipping-taxable","24":"purchasable","25":"product-type-variable","26":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/61728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=61728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/61729"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=61728"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=61728"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=61728"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=61728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}